VSTM Stock Overview
A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Verastem, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.00 |
| 52 Week High | US$14.22 |
| 52 Week Low | US$2.10 |
| Beta | 0.14 |
| 11 Month Change | 21.95% |
| 3 Month Change | 62.60% |
| 1 Year Change | -40.92% |
| 33 Year Change | -87.56% |
| 5 Year Change | -75.67% |
| Change since IPO | -96.99% |
Recent News & Updates
Recent updates
Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade
May 26Verastem: Moving Forward
Sep 13Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?
Sep 01
Verastem Non-GAAP EPS of -$0.11 in-line
Aug 08Verastem: Looking Increasingly Attractive
Jun 29Verastem: Time To Take My Position Out Of Mothball
Apr 19Vectoring In On Verastem
Jan 12Verastem: Buying Opportunity Following Unjustified Sell-Off
Sep 22Shareholder Returns
| VSTM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | 2.4% | 2.2% |
| 1Y | -40.9% | 16.2% | 31.7% |
Return vs Industry: VSTM underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: VSTM underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| VSTM volatility | |
|---|---|
| VSTM Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VSTM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VSTM's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 73 | Dan Paterson | www.verastem.com |
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205.
Verastem, Inc. Fundamentals Summary
| VSTM fundamental statistics | |
|---|---|
| Market cap | US$174.91m |
| Earnings (TTM) | -US$93.45m |
| Revenue (TTM) | US$10.00m |
17.8x
P/S Ratio-1.9x
P/E RatioIs VSTM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VSTM income statement (TTM) | |
|---|---|
| Revenue | US$10.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$10.00m |
| Other Expenses | US$103.45m |
| Earnings | -US$93.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.10 |
| Gross Margin | 100.00% |
| Net Profit Margin | -934.54% |
| Debt/Equity Ratio | 126.2% |
How did VSTM perform over the long term?
See historical performance and comparison